STOCK MARKET BSE NSE

Purdue sues Dr Reddy’s for patent infringement

Published: 09th April 2013 08:37 AM  |   Last Updated: 09th April 2013 08:37 AM   |  A+A-

In yet another patent infringment suit, Dr Reddy’s Laboratories Ltd was dragged to court, by Purdue Pharma LP, which filed a petition in New Jersey Federal Court for alleged infringement of its insomnia drug — Intermezzo.

Stanford, Conn-based Purdue’s Intermezzo consists of tablets containing 1.75 mg and 3.5 mg of zolpidem tartrate. The US Food and Drug Administration (US FDA)  gave its approval for the drug in November, 2011.

As per the complaint, DRL in February filed its abbreviated new drug application with the US FDA that includes Paragraph IV certifications saying that its product wouldn’t violate Purdue’s patents or that those patents are invalid.

The suit involves three patents held by Transcept Pharmaceuticals Inc and exclusively licensed to Purdue for an under-the-tongue sleep aid that targets middle-of-the-night awakenings.

“Dr. Reddy’s has infringed the ’809 Patent under 35 U.S.C. 271(e)(2)(A) by virtue of submitting ANDA No. 204503 with a paragraph IV certification and seeking FDA approval of ANDA No. 204503 to market a generic version of Intermezzo® prior to the expiration of the ’809 Patent,” Purdue said in its complaint dated April 7.

Last year, DRL was dragged to court by US-based Bristol-Myers over its cancer drug Ixempra. Besides it also contested multiple suits including those filed by Pozen regarding a generic version of arthritic drug Vimovo, Takeda of Japan over patent infringement of its gastrointestinal drug Dexilant and Roche Palo ALTO LLC and Helsinn Healthcare SA’s patent litigation suit for anti-nausea drug Aloxi.

In August, 2012, DRL lost a litigation suit for migrane drug Treximet filed by North Carolina-based Pozen Inc, way back in 2009.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp